Waldenstrom's Macroglobulinemia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Pirtobrutinib and Venetoclax in Waldenstr öm Macroglobulinemia
Conditions: Waldenstrom Macroglobulinemia; B-Cell Lymphoproliferative Disorder Interventions: Drug: Pirtobrutinib; Drug: Venetoclax; Drug: Allopurinol Sponsors: Dana-Farber Cancer Institute; Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2023 Category: Research Source Type: clinical trials
